No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LEXX Lexaria Bioscience
- 2.2850
- +0.0350+1.56%
Trading Apr 19 09:59 ET
29.44MMarket Cap-3410P/E (TTM)
2.2900High2.2600Low4.57KVolume2.2600Open2.2500Pre Close10.44KTurnover0.04%Turnover RatioLossP/E (Static)12.89MShares6.850052wk High4.52P/B25.82MFloat Cap0.648852wk Low--Dividend TTM11.30MShs Float12.5000Historical High--Div YieldTTM1.33%Amplitude0.6488Historical Low2.2830Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Lexaria Bioscience, Biosig Technologies, BIMI Holdings Among Healthcare Movers
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersClene (NASDAQ:CLNN) shares moved upwards by 54.9% to $0.48 during Tuesday's after-market session. The company's market cap stands at $61.6 million. Talphera (NASDAQ:TLPH) shares moved upwards b
Express News | Lexaria Bioscience - Subject Recruitment to Begin Immediately & Co to Announce as Soon as First Dosing Has Begun, Expected Within 30 Days or Less
Express News | Lexaria Bioscience Corp: Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
Human Pilot Study #2 Approved KELOWNA, BC / ACCESSWIRE / April 16, 2024 / Lexaria Bioscience Corp. , a global innovator in drug
Lexaria Awarded New Patents
Lexaria receives new patents in the fields of epilepsy and anti-viral agentsKELOWNA, BC / ACCESSWIRE / April 2, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria")
Comments
$Lexaria Bioscience(LEXX.US$
Company AnnouncementsLexaria Bioscience Showcases Drug Delivery Breakthrough
Lexaria Bioscience Corp. (LEXX) has released an update. Lexaria Bioscience Corp., a leader in drug delivery platforms, will present its latest advancements in improving GLP-1 drugs using its DehydraTECH technology at the 14th Annual LD Micro Invitational in New York. CEO Chris Bunka is set to discuss recent discoveries and forthcoming studies that could significantly impact...
Company AnnouncementsLexaria Bioscience Showcases Drug Delivery Breakthrough
Lexaria Bioscience Corp. (LEXX) has released an update. Lexaria Bioscience Corp., a leader in drug delivery platforms, will present its latest advancements in improving GLP-1 drugs using its DehydraTECH technology at the 14th Annual LD Micro Invitational in New York. CEO Chris Bunka is set to discuss recent discoveries and forthcoming studies that could significantly impact...
1
Update
$Lexaria Bioscience(LEXX.US$ Lexaria To Begin Diabetes And Weight Loss Animal Study WEIGHT-A24-1
Benzinga· 4 mins ago
Benzinga· 4 mins ago
1
$Lexaria Bioscience(LEXX.US$ glp is like AI.. everyone's chasing the problem with bioscience biotech to go from phase one phase two phase 3 human trials final most companies never make it that far it's a series of disappointments by the time it ever gets approved Lily will be a 2 trillion dollar company
$Lexaria Bioscience(LEXX.US$ Something dont add up?
6
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg